Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Acasti Pharma (ACST)

Acasti Pharma (ACST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Acasti Pharma Announces 1-for-6 Reverse Stock Split PR Newswire - Fri Jul 7, 2023

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of...

ACST : 2.90 (-0.97%)
Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023 PR Newswire - Wed Jul 5, 2023

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel injectable...

ACST : 2.90 (-0.97%)
Acasti Pharma Reports Fiscal Year 2023 Operational Results PR Newswire - Fri Jun 23, 2023

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of...

ACST : 2.90 (-0.97%)
Short Week in U.S. Baystreet - Fri Jun 16, 2023

Monday U.S. Markets are closed for “Juneteenth” holiday. Canada Economic Lookahead ...

FDX : 265.84 (+0.12%)
LZB : 33.11 (-0.12%)
ACST : 2.90 (-0.97%)
KBH : 65.60 (+2.07%)
WGO : 63.07 (+0.90%)
SCS : 12.07 (+1.26%)
ACN : 308.01 (-0.32%)
DRI : 156.10 (-0.28%)
FDS : 421.47 (+0.66%)
KMX : 69.59 (+0.53%)
BIGG.CN : 0.1600 (unch)
ASE.CN : 1.2200 (+4.27%)
Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025 PR Newswire - Mon May 8, 2023

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of...

ACST : 2.90 (-0.97%)
Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND PR Newswire - Tue Apr 4, 2023

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, specialty pharma company advancing drug candidates for rare and...

ACST : 2.90 (-0.97%)
Acasti Pharma Inc. Announces the Resignation of a Director PR Newswire - Thu Mar 30, 2023

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST) a late-stage, specialty pharma company advancing three clinical stage drug...

ACST : 2.90 (-0.97%)
Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange PR Newswire - Mon Mar 13, 2023

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST) a late-stage, specialty pharma company advancing three clinical...

ACST : 2.90 (-0.97%)
Acasti Pharma Recognizes Rare Disease Day PR Newswire - Tue Feb 28, 2023

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical...

ACST : 2.90 (-0.97%)
Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year? Zacks - Tue Feb 28, 2023

Here is how Acasti Pharma (ACST) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.

ACST : 2.90 (-0.97%)
AUTL : 4.00 (-1.96%)

Barchart Exclusives

Buy the Dip: This Top-Rated Cathie Wood Stock Has 39% Upside Potential Barchart - Fri Apr 26, 3:10PM CDT
Discover why Wall Street analysts are largely bullish on DraftKings, with expectations of significant upside, in our latest deep dive on the stock's performance and future prospects. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot